Phase I Trial of Docetaxel With Perifosine

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study of the drug perifosine given in combination with docetaxel. Perifosine is an oral anti-cancer agent that has been used in more than 140 people. Docetaxel is a standard chemotherapy agent used in many types of cancer. This study is designed to determine the highest dose of perifosine that can be administered to people every day while they are receiving docetaxel with or without a steroid called prednisone, without severe or prolonged nausea, vomiting and diarrhea. This study starts with patients taking 50 mg/day and goes up to 150 mg/day.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AEterna Zentaris
• Treatments: Docetaxel; Prednisone

Criteria

Inclusion Criteria

• Patients must have histologically or cytologically confirmed diagnosis of cancer for which treatment with single agent docetaxel would be an appropriate treatment option.

• At least 18 years of age.

• Patients may be currently receiving docetaxel using the schedule in the protocol, as long as the treating investigator has reasonable expectation that the patient will continue to receive docetaxel for 2 or more additional cycles. The current regimen does not count towards the 2 regimens as long as the patient is not progressing on therapy..

• Patients must have a life expectancy of more than 3 months.

• Patients must have a performance status of 0 to 2 according to the ECOG criteria.

• Patients must have normal organ and marrow function as defined in the protocol:

leukocytes >=4,000/microL, absolute neutrophil count >=1,500/microL, platelets >=100,000/microL, HCT > 28%, total bilirubin < 1.5 x upper limit of normal, AST (SGOT)/ALT (SGPT) <=2.5 X institutional upper limit of normal, creatinine <= 2.5 mg/dl

• Patients must have recovered from acute toxicity related to prior therapy, excluding alopecia, including surgery or radiotherapy.

• Patients must be able to ingest oral medications.

• Female patients who are pregnant or lactating are ineligible. All females of childbearing potential must have a negative serum pregnancy test within 72 hours of treatment. Men and women of childbearing potential must agree to employ adequate contraception to prevent pregnancy while on therapy and for four weeks after the completion of treatment.

• Patients must have ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

• Patients may not be receiving any other investigational agents or devices.

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine).

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection and psychiatric illness/social situations that would limit compliance with study requirements.

• HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with perifosine.

• Patients with a history of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within 6 months of enrollment) or New York Heart Assoc. class II-IV congestive heart failure.

• Patients with a history of hypersensitivity reaction to products containing Polysorbate 80 (Tween 80).